Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T17:07:11.034Z.
Calculation as of: 2026-10-06T17:07:11.034Z.
Quote observation: 2026-10-06T16:46:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bcc3f1894ec499320e43c54a24f2662d6ad9e54feca4b92c79248349e67b8166
Current P/S: FMP quote market capitalization / TTM revenue. Historical estimates use price and reported weighted-average shares; daily points use adjusted close × quarterly weighted-average shares / TTM revenue. Historical series through 2021-03-31.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
PS RATIO AVG TTM
N/A
PS RATIO AVG 3Y
N/A
PS RATIO AVG 5Y
N/A
PS RATIO AVG 10Y
N/A
PS RATIO AVG 15Y
N/A
PS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$4.08M
PS Ratio
3.67
TTM Avg
2.69
3Y Avg
11.87
5Y Avg
15.54
Market Cap
$4.34M
PS Ratio
13.66
TTM Avg
8.42
3Y Avg
22.33
5Y Avg
51.13
Market Cap
$3.84M
PS Ratio
N/A
TTM Avg
2863.91
3Y Avg
2004.87
5Y Avg
2004.87
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRI Bio, Inc. (GRI) | $4.15M | N/A | N/A | N/A | N/A |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $4.08M | 3.67 | 2.69 | 11.87 | 15.54 |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.23M | 2.07 | 2.70 | 2.70 | 2.70 |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.07M | N/A | 3.25 | 5.35 | 5.73 |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.00M | N/A | 1.94 | 5.55 | 4.76 |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.34M | 13.66 | 8.42 | 22.33 | 51.13 |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.84M | N/A | 2863.91 | 2004.87 | 2004.87 |
| Evogene Ltd. (EVGN)vs › | $3.79M | 2.90 | 2.12 | 1.98 | 176.94 |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.52M | N/A | N/A | N/A | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.64M | 2.49 | 15.60 | 53.90 | 53.90 |
Half-year reporter: no trailing two-half-year basis, because the newest reported periods are not each a half-year of 150 to 215 days.
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PS RATIO |
|---|---|
| 2021-03-31 | 53723.62 |
| 2021-03-30 | 52102.65 |
| 2021-03-29 | 54649.89 |
| 2021-03-26 | 51060.60 |
| 2021-03-25 | 50713.25 |
| 2021-03-24 | 50018.54 |
| 2021-03-23 | 57660.27 |
| 2021-03-22 | 59628.59 |
| 2021-03-19 | 58123.40 |
| 2021-03-18 | 61481.13 |
| 2021-03-17 | 62870.53 |
| 2021-03-16 | 63102.10 |
| 2021-03-15 | 67386.09 |
| 2021-03-12 | 64375.72 |
| 2021-03-11 | 68312.36 |
| 2021-03-10 | 60670.64 |
| 2021-03-09 | 59975.94 |
| 2021-03-08 | 60786.43 |
| 2021-03-05 | 57903.41 |
| 2021-03-04 | 61365.34 |
| 2021-03-03 | 67154.53 |
| 2021-03-02 | 69238.63 |
| 2021-03-01 | 71785.87 |
| 2021-02-26 | 70743.82 |
| 2021-02-25 | 70859.60 |
| 2021-02-24 | 79774.95 |
| 2021-02-23 | 72480.58 |
| 2021-02-22 | 75259.38 |
| 2021-02-19 | 81511.70 |
| 2021-02-18 | 85101.00 |
| 2021-02-17 | 86374.62 |
| 2021-02-16 | 88574.51 |
| 2021-02-12 | 90658.61 |
| 2021-02-11 | 87995.59 |
